Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC
Upon determination of eligibility, all patients will be receive:
- Irinotecan + Carboplatin + Imatinib
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
Anthony Greco, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI LUN 59
NCT00193349
September 2002
December 2007
Name | Location |
---|